- Home
- GKOS
GKOS
Glaukos Corporation
as of 12-03-2025 3:42pm EST
$107.89
+$1.82
+1.72%
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Chart Type:
Time Range:
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 5.4B | IPO Year: | 2015 |
| Target Price: | $122.08 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $73.16 - $163.71 | Next Earning Date: | 10-29-2025 |
| Revenue: | $469,820,000 | Revenue Growth: | 30.38% |
| Revenue Growth (this year): | 30.89% | Revenue Growth (next year): | 24.36% |
AI-Powered GKOS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.47%
70.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Glaukos Corporation (GKOS)
Thurman Alex R.
Sell
SVP & CHIEF FINANCIAL OFFICER
GKOS Nov 25, 2025
Avg Cost/Share
$105.00
Shares
315
Total Value
$33,075.00
Owned After
50,488
SEC Form 4
Gilliam Joseph E
Sell
PRESIDENT & COO
GKOS Nov 18, 2025
Avg Cost/Share
$90.00
Shares
19,340
Total Value
$1,740,600.00
Owned After
92,366
SEC Form 4
Navratil Tomas
Sell
CHIEF DEVELOPMENT OFFICER
GKOS Sep 22, 2025
Avg Cost/Share
$83.75
Shares
517
Total Value
$43,541.05
Owned After
76,884
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Thurman Alex R. | GKOS | SVP & CHIEF FINANCIAL OFFICER | Nov 25, 2025 | Sell | $105.00 | 315 | $33,075.00 | 50,488 | |
| Gilliam Joseph E | GKOS | PRESIDENT & COO | Nov 18, 2025 | Sell | $90.00 | 19,340 | $1,740,600.00 | 92,366 | |
| Navratil Tomas | GKOS | CHIEF DEVELOPMENT OFFICER | Sep 22, 2025 | Sell | $83.75 | 517 | $43,541.05 | 76,884 |
Latest Glaukos Corporation News
GKOS Breaking Stock News: Dive into GKOS Ticker-Specific Updates for Smart Investing
Zacks
Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue?
📊
AI Sentiment
Positive
7/10
Compare GKOS vs Leading Stocks
See how GKOS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GKOS Glaukos Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.